Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DFC413 and 68Ga-NNS309 in Solid Tumors
NCT07261631Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- May 2029
- Modality
- Radiopharmaceutical
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-DFC413 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer and 3 more, sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 6 weeks, Adverse Events and Serious Adverse Events at 42 months and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
177Lu-DFC413
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)breast cancertriple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07261631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261631.